Submit Manuscript  

Article Details


Integrative Exome Sequencing Analysis in Castration-Resistant Prostate Cancer in Chinese Population

[ Vol. 21 , Issue. 2 ]

Author(s):

Lifang Hao, Hui Li*, Su Zhang, Yanlei Yang, Zhenzhen Xu, Yanfen Zhang and Zhongcheng Liu*   Pages 140 - 148 ( 9 )

Abstract:


Background: Castration-resistant Prostate Cancer (CRPC) is a fatal disease with rapid growth. The malignancy usually presents with metastasis and poor prognosis, and causes 100% mortality. Therefore, the treatment of CRPC is extremely challenging, and its pathogenesis needs to be elucidated urgently.

Objective: The high throughput sequencing technology was used to sequence the whole exome associated with CRPC, to explore the molecular mechanism of CRPC, and to find the potential therapeutic targets.

Methods: We performed whole-exome sequencing of FFPE tissue from 11 Chinese adult male patients. Genomic DNA was fragmented and enriched for whole-exome sequencing using the QiAamp DNA FFPE Tissue KIT, sequenced on an Illumina HiSeq2000 platform, and the relevant genes were analyzed using biological information. Finally, immunohistochemistry method was used to detect the phosphorylation level of LATS1 in CRPC tissues of MST1 mutant and non-mutant patients.

Results: We have screened 85 significant mutant genes with relatively high mutation rates of TP53, AR, KMT2, DMAPK1, PIK3R1, SH2B3, WHSC1, KMT2D, MST1 and MAPK1. We first found that MST1 has multiple mutations in CRPC patients, and the MST1 plays an important role in the Hippo pathway. Immunohistochemistry results showed that the phosphorylation level of LATS1 in the mutant patients was significantly lower than that in the non-mutant patients.

Conclusion: We speculate that MST1 would be a new potential target for the treatment of CRPC by regulating Hippo signaling pathway. The results provided an important clue to the molecular mechanism of CRPC.

Keywords:

CRPC, MST1 mutation, whole-exome sequencing, bioinformatics analysis, Hippo signaling pathway, LATS1.

Affiliation:

College of Pharmaceutical Sciences, Hebei University, Baoding 071002, Department of Urology, Peking University International Hospital, Beijing 102206, College of Pharmaceutical Sciences, Hebei University, Baoding 071002, College of Pharmaceutical Sciences, Hebei University, Baoding 071002, College of Pharmaceutical Sciences, Hebei University, Baoding 071002, College of Pharmaceutical Sciences, Hebei University, Baoding 071002, College of Pharmaceutical Sciences, Hebei University, Baoding 071002



Read Full-Text article